Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8827556 | Transplantation Proceedings | 2017 | 6 Pages |
Abstract
In an era of highly effective direct acting antiviral therapy, rapid HCV recrudescence in grafts from DCD donors should not compromise long-term morbidity or mortality. In the context of rising wait-list mortality, it is prudent to use all available sources to expand the pool of donor organs, and our data support the practice of using extended-criteria DCD grafts based on donor age. Notwithstanding that, clinicians should be aware that HCV recrudescence is more rapid in DCD recipients, and early post-transplant anti-viral therapy is indicated to prevent graft injury.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
S.A. Townsend, M.A. Monga, P. Nightingale, D. Mutimer, A.M. Elsharkawy, A. Holt,